Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
J Gastroenterol Hepatol. 2021 Jan;36(1):204-207. doi: 10.1111/jgh.15112. Epub 2020 Jun 5.
Coronavirus disease 2019 (COVID-19) has attracted increasing worldwide attention. While diabetes is known to aggravate COVID-19 severity, it is not known whether nondiabetic patients with metabolic dysfunction are also more prone to more severe disease. The association of metabolic associated fatty liver disease (MAFLD) with COVID-19 severity in nondiabetic patients was investigated here.
The study cohort comprised 65 patients with (i.e. cases) and 65 patients without MAFLD (i.e. controls). Each case was randomly matched with one control by sex (1:1) and age (±5 years). The association between the presence of MAFLD (as exposure) and COVID-19 severity (as the outcome) was assessed by binary logistic regression analysis.
In nondiabetic patients with COVID-19, the presence of MAFLD was associated with a four-fold increased risk of severe COVID-19; the risk increased with increasing numbers of metabolic risk factors. The association with COVID-19 severity persisted after adjusting for age, sex, and coexisting morbid conditions.
Health-care professionals caring for nondiabetic patients with COVID-19 should be cognizant of the increased likelihood of severe COVID-19 in patients with MAFLD.
新型冠状病毒病 2019（COVID-19）引起了全世界越来越多的关注。已知糖尿病会加重 COVID-19 的严重程度，但尚不清楚代谢功能障碍的非糖尿病患者是否也更容易发生更严重的疾病。本研究旨在探讨代谢相关脂肪性肝病（MAFLD）与非糖尿病患者 COVID-19 严重程度的关系。
本研究队列包括 65 例（即病例）和 65 例非 MAFLD 患者（即对照）。每个病例均通过性别（1:1）和年龄（±5 岁）与一名对照进行随机匹配。采用二项逻辑回归分析评估 MAFLD 的存在（作为暴露因素）与 COVID-19 严重程度（作为结局）之间的关系。
在患有 COVID-19 的非糖尿病患者中，MAFLD 的存在与 COVID-19 严重程度增加四倍相关；随着代谢危险因素数量的增加，风险也随之增加。在调整了年龄、性别和并存的合并症后，这种与 COVID-19 严重程度的关联仍然存在。
照顾 COVID-19 非糖尿病患者的医疗保健专业人员应意识到 MAFLD 患者 COVID-19 严重程度增加的可能性。
